[Clinical study of levonorgestrel-releasing intrauterine system for adenomyosis].
OBJECTIVE
To investigate the clinical efficacy of levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of adenomyosis.


METHODS
Seventy patients with adenomyosis diagnosed according to clinical symptoms, magnetic resonance imaging (MRI) findings, laparoscopy and/or color-Doppler ultrasound imaging were treated with LNG-IUS, and the menstrual blood volume, dysmenorrhea, uterine volume, hepatic function and serum lipids were observed and evaluated.


RESULTS
In the first month of treatment, the menstrual blood size was reduced significantly to (35-/+12)% of that before treatment (P<0.01), and further to (7-/+4)% in the twelfth month (P<0.01). The average uterine volume was decreased by 18.6% (P<0.05) after the treatment, and dysmenorrhea was obviously relieved or completely disappeared alleviated. The condition of anemia was also improved rapidly, and no obvious side-effects on hepatic function and serum lipids were observed.


CONCLUSIONS
LNG-IUS is an effective and safe therapy for adenomyosis.
He
Shu-ming
SM
Xiaolan Station of Zhongnan University, National Hepatobiliary and Enteric Surgery Research CenterìMinistry of Health, Zhongshan 528415, China. hsm@xlrmyy.com
Zhang
Yang-de
YD
D000328:Adult; D003271:Contraceptive Agents, Female / Q000008:administration & dosage / Q000627:therapeutic use; D004715:Endometriosis / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007436:Intrauterine Devices, Medicated; D016912:Levonorgestrel / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
D003271:Contraceptive Agents, Female; D016912:Levonorgestrel